Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials

Corporate Breaking News

Home : Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials

Jun 03 2019	Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
BASEL, Switzerland, June 3, 2019 /PRNewswire/ -- Novartis announced today new data and clinical trial updates in NSCLC at the ASCO 2019 Annual Meeting. This includes primary efficacy results from the GEOMETRY mono-1 Phase II clinical trial demonstrating that investigational MET inhibitor...


Source:https://www.prnewswire.com:443/news-releases/novartis-shows-growing-strength-in-lung-cancer-innovation-with-new-capmatinib-investigational-data-and-novel-canakinumab-clinical-trials-300860389.html

Related News
» Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination » Nordic Nanovector: European Patent Granted for Betalutin® or Humalutin® in Combination With Anti-CD20 Antibodies for Treating NHL